Central Nervous System Stimulants

"Central Nervous System Stimulants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Descriptor ID	D000697
MeSH Number(s)	D27.505.696.282 D27.505.954.427.220
Concept/Terms	Central Nervous System Stimulants Central Nervous System Stimulants Central Stimulants Stimulants, Central Analeptics Analeptics Analeptic Drugs Drugs, Analeptic Analeptic Agents Agents, Analeptic

Below are MeSH descriptors whose meaning is more general than "Central Nervous System Stimulants".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Central Nervous System Stimulants [D27.505.696.282]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Central Nervous System Stimulants [D27.505.954.427.220]

Below are MeSH descriptors whose meaning is related to "Central Nervous System Stimulants".

Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Stimulants".

Central Nervous System Stimulants
Aphrodisiacs
Appetite Stimulants
Convulsants

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Central Nervous System Stimulants" by people in this website by year, and whether "Central Nervous System Stimulants" was a major or minor topic of these publications.

Bar chart showing 59 publications over 24 distinct years, with a maximum of 7 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	2	0	2
1999	0	1	1
2001	0	1	1
2003	1	0	1
2004	1	0	1
2005	2	1	3
2006	1	3	4
2007	6	0	6
2008	5	1	6
2009	2	2	4
2010	2	0	2
2011	2	0	2
2012	7	0	7
2013	3	0	3
2014	1	1	2
2016	1	0	1
2017	2	1	3
2018	1	0	1
2019	1	1	2
2020	2	0	2
2022	1	0	1
2023	0	1	1
2024	0	1	1
2026	2	0	2

Below are the most recent publications written about "Central Nervous System Stimulants" by people in Profiles.

Drumright LN, Hayashi K, Mehta SH, Pho MT, DeBeck K, Crane HM, Genberg BL, Cooper H, Napravnik S, Zule W, Mayer KH, Stopka TJ, Bamford L, Miller WC, Yendewa G, Go VF, Burkholder G, Korthuis PT, Christopoulos K, Seal DW, Feinberg J, Friedmann PD, Mok WY, Falade-Nwulia O, Kyle RP, Smith GS, Keruly JC, Fredericksen RJ, Hahn AW, Whitney BM, Mixson LS, Mandler RN, Moore RD, Saag MS, Milloy MJ, Kirk GD, Delaney JA, Chander G, Tsui JI. Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone. Drug Alcohol Depend. 2026 Nov 01; 288:113362.

View in: PubMed
Jaffe K, Evans EA. From Control to Care: Reframing Medication Access Policies Through Public Health Ethics. J Law Med Ethics. 2026; 54(1):95-97.

View in: PubMed
Estadt AT, Kline D, Miller WC, Feinberg J, Hurt CB, Mixson LS, Friedmann PD, Lowe K, Tsui JI, Young AM, Cooper H, Korthuis PT, Pho MT, Jenkins W, Westergaard RP, Go VF, Brook D, Smith G, Rice DR, Lancaster KE. Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities. Harm Reduct J. 2024 11 29; 21(1):214.

View in: PubMed
Estadt AT, Miller WC, Kline D, Whitney BM, Young AM, Todd Korthuis P, Stopka TJ, Feinberg J, Zule WA, Pho MT, Friedmann PD, Westergaard RP, Eagen KV, Seaman A, Ma J, Go VF, Lancaster KE. Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities. Int J Drug Policy. 2025 07; 141:104222.

View in: PubMed
Tonyushkina KN, Obi O, Visintainer P, Cobb V, Reiter E, Allen HF. Children with Attention Deficit Hyperactivity Disorder Are More Likely to Fail Growth Hormone Stimulation Testing than Children without Attention Deficit Hyperactivity Disorder: A Retrospective Chart Review. Horm Res Paediatr. 2023; 96(3):298-305.

View in: PubMed
Yang T, Zang S, Wang Y, Zhu Y, Jiang L, Chen X, Zhang X, Cheng J, Gao R, Xiao H, Wang J. Methamphetamine induced neuroinflammation in mouse brain and microglial cell line BV2: Roles of the TLR4/TRIF/Peli1 signaling axis. Toxicol Lett. 2020 Oct 15; 333:150-158.

View in: PubMed
Drazdowski TK, Kelly LM, Kliewer WL. Motivations for the nonmedical use of prescription drugs in a longitudinal national sample of young adults. J Subst Abuse Treat. 2020 07; 114:108013.

View in: PubMed
Mazhar H, Foster BC, Necyk C, Gardiner PM, Harris CS, Robaey P. Natural Health Product-Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication. J Child Adolesc Psychopharmacol. 2020 02; 30(1):38-47.

View in: PubMed
Chen L, Zhou L, Yu P, Fang F, Jiang L, Fei J, Xiao H, Wang J. Methamphetamine exposure upregulates the amyloid precursor protein and hyperphosphorylated tau expression: The roles of insulin signaling in SH-SY5Y cell line. J Toxicol Sci. 2019; 44(7):493-503.

View in: PubMed
Jin H, Ogunbajo A, Mimiaga MJ, Duncan DT, Boyer E, Chai P, Dilworth SE, Carrico AW. Over the influence: The HIV care continuum among methamphetamine-using men who have sex with men. Drug Alcohol Depend. 2018 11 01; 192:125-128.

View in: PubMed

People

Explore

Similar Concepts

Top Journals